Status:
RECRUITING
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Lead Sponsor:
Lahey Clinic
Conditions:
Non-muscle Invasive Bladder Cancer (NMIBC)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
Eligibility Criteria
Inclusion
- AUA high-risk bladder cancer1
- Received induction BCG or gemcitabine/docetaxel
- Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)
Exclusion
- High-risk NMIBC within 3 years
- Prior induction intravesical therapy
- Variant histology
- Concurrent upper tract disease
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2029
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT07187063
Start Date
January 1 2025
End Date
January 1 2029
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lahey Hospital and Medical Center
Burlington, Massachusetts, United States, 01805